Get the Stockscreener App
47.39
2.11%
0.98
After Hours:
47.39
Ptc Therapeutics Inc stock is traded at $47.39, with a volume of 1.04M.
It is up +2.11% in the last 24 hours and down -17.11% over the past month.
See More
Previous Close:
$46.41
Open:
$46.33
24h Volume:
1.04M
Relative Volume:
1.21
Market Cap:
$3.56B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-7.9781
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+17.62%
1M Performance:
-17.11%
6M Performance:
+28.05%
1Y Performance:
+88.35%
1-Day Range:
$45.95
$47.96
1-Week Range:
$39.03
$48.60
52-Week Range:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
47.39 | 3.56B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Lobbying Update: $20,000 of PTC THERAPEUTICS lobbying was just disclosed - Nasdaq
Walleye Capital LLC Invests $4.97 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Federated Hermes Inc. Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million - Quantisnow
Russell Investments Group Ltd. Sells 61,542 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Renaissance Technologies LLC Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Trading Up 6.8%Time to Buy? - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results - Quantisnow
MELAS Syndrome Therapeutics Market Size in 7MM is expected - openPR.com
PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results | PTCT Stock News - GuruFocus
PTC Therapeutics Reveals Q1 2025 Earnings Date: Key Financial Updates Coming May 6 - Stock Titan
Cautious Hold Rating for PTC Therapeutics Amidst FDA Reviews and Revenue Uncertainties - TipRanks
Alliancebernstein L.P. Buys 139,596 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
ADAR1 Capital Management LLC Purchases 28,023 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
American Century Companies Inc. Has $2.72 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results - marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Headlands Technologies LLC - MarketBeat
Lee Scott Golden Sells 897 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Leigh Syndrome Treatment Market Set to Witness Significant - openPR.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Vanguard Group Inc. - MarketBeat
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Business And Shares Still Trailing The Industry - simplywall.st
Wellington Management Group LLP Sells 3,105,676 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Trexquant Investment LP Has $14.15 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
14,300 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by KLP Kapitalforvaltning AS - MarketBeat
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 By Investing.com - Investing.com Australia
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 - Investing.com
PTC Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Pictet Asset Management Holding SA Buys 381,319 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given New $75.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc. - MarketBeat
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):